Is CBT better than other depression treatments?
CBT clearly beats control conditions such as care as usual and waitlist, but it does not clearly beat other psychotherapies, and it matches antidepressants in the short term. This comes from a meta-analysis of randomized trials in World Psychiatry that pooled 409 trials with 52,702 patients, the largest meta-analysis ever conducted of a specific type of psychotherapy for a mental disorder.
The authors' own conclusion is the part worth holding onto: the efficacy of CBT for depression is documented across formats, ages, target groups and settings, but its superiority over other psychotherapies does not emerge clearly from the data.
What the data show:
- Against control conditions: moderate to large benefit, g=0.79 (95% CI: 0.70-0.89)
- Against antidepressants: no significant difference short term, larger effect at 6-12 months
- Against other psychotherapies: g=0.06 (95% CI: 0-0.12), non-significant in most sensitivity analyses
- Combined treatment: better than medication alone, not better than CBT alone
Dr. Kumar’s Take
This is a comprehensive answer to the question of how CBT compares to everything else, and the honest reading is more modest than the headline. Against waitlist and care as usual, CBT produces a moderate to large effect that held up in sensitivity analyses and was still significant at 6-12 month follow-up. Against another active psychotherapy, the advantage was g=0.06 with a confidence interval touching zero, and it disappeared in most sensitivity analyses. I read that as evidence that a structured, active, evidence-based psychotherapy helps, not that the cognitive behavioral label is the ingredient.
The comparison with medication is the part I use most in clinic. Short term, the two were statistically indistinguishable. At 6-12 months, CBT came out ahead by g=0.34, though the authors flag that the number of trials was small and the difference did not survive every sensitivity analysis. That is a reason to offer psychotherapy to a patient who wants durable benefit, not a reason to promise one.
The combined treatment result deserves attention too. Adding CBT to medication beat medication alone at both time points, but combined treatment did not beat CBT alone at either time point. For a patient who prefers to avoid an antidepressant, that is a defensible starting position.
Study Snapshot
This was a systematic review and random-effects meta-analysis, not a single trial. The authors searched PubMed, PsycINFO, Embase and the Cochrane Library, then split the included trials into subsets for separate analyses.
- 409 randomized trials, 518 comparisons, 52,702 patients with depression
- Comparators analyzed separately: control conditions such as care as usual and waitlist, other psychotherapies, pharmacotherapies, and combined treatment
- Formats and populations analyzed separately: unguided self-help, institutional settings, children and adolescents
Trial quality increased significantly over time, with more trials at low risk of bias, fewer waitlist control groups, and larger sample sizes. Effect sizes did not shrink by publication period when trials were grouped as before 2001, 2001-2010, and after 2011.
Results in Real Numbers
CBT vs Control Conditions
Main effect size: g=0.79 (95% CI: 0.70-0.89)
- Moderate to large effect against care as usual and waitlist
- Effect remained similar in sensitivity analyses
- Still significant at 6-12 month follow-up
- No reduction in effect size by publication year
CBT vs Other Psychotherapies
Main effect size: g=0.06 (95% CI: 0-0.12)
- Statistically significant, but the difference is small
- Became non-significant in most sensitivity analyses
- The authors conclude that superiority of CBT over other psychotherapies does not emerge clearly from this meta-analysis
CBT vs Pharmacotherapies (Antidepressants)
Short term: no significant difference
- Long-term advantage: CBT significantly larger at 6-12 months, g=0.34 (95% CI: 0.09-0.58)
- The authors note the number of trials for that comparison was small, and the difference was not significant in all sensitivity analyses
Combined Treatment (Therapy + Medication)
vs pharmacotherapy alone: g=0.51 (95% CI: 0.19-0.84) short term
- Long term: g=0.32 (95% CI: 0.09-0.55) at 6-12 months
- vs CBT alone: not more effective at either time point
Special Formats and Populations
- Unguided self-help CBT: g=0.45 (95% CI: 0.31-0.60), effective without a therapist guiding the work
- Institutional settings: g=0.65 (95% CI: 0.21-1.08)
- Children and adolescents: g=0.41 (95% CI: 0.25-0.57)
Who Benefits Most
The efficacy of CBT for depression was documented across different formats, ages, target groups and settings.
- Age: adults, and children and adolescents (g=0.41)
- Setting: institutional settings (g=0.65)
- Format: therapist-delivered CBT, and unguided self-help (g=0.45)
Patients who may particularly benefit:
- Those seeking benefit that holds at 6-12 months, where CBT outperformed pharmacotherapy
- Those who prefer a non-medication approach, since CBT matched antidepressants short term
- Those already on an antidepressant, since adding CBT beat medication alone
- Those without access to a therapist, since unguided self-help still produced a moderate effect
Safety, Limits, and Caveats
Trial quality improved over time. The number of trials at low risk of bias rose, waitlist control groups became less common, and sample sizes grew. Effect sizes did not fall across publication periods.
Key limitations:
- The advantage over other psychotherapies is small and fragile. g=0.06 with a confidence interval reaching zero, and non-significant in most sensitivity analyses
- The long-term edge over medication rests on few trials. The authors state the number of trials was small and the difference was not significant in all sensitivity analyses
- Control conditions are not neutral. Care as usual and waitlist comparisons generate the largest effects in this dataset
- Group-level effect sizes do not predict what any one patient will experience
Clinical implications:
- CBT has the largest evidence base of any psychotherapy for depression
- Other psychotherapies are close enough that patient preference is a reasonable basis for choosing
- Adding medication to CBT did not beat CBT alone in this analysis
- Combined treatment did beat medication alone, at both short and long term
Practical Takeaways
- CBT beats care as usual and waitlist by a moderate to large margin, g=0.79
- CBT matches antidepressants short term and was larger at 6-12 months, g=0.34
- The edge over other psychotherapies is g=0.06 and does not hold up in most sensitivity analyses
- Combined treatment beats medication alone at short and long term, but not CBT alone
- Unguided self-help CBT works, g=0.45, when a therapist is not available
- Benefit against control conditions was still significant at 6-12 months
What This Means for Depression Treatment
This meta-analysis confirms CBT as a well-evidenced first-line psychotherapy for depression, tested in 409 randomized trials across formats, ages, target groups and settings. The benefit against control conditions is solid and durable to 6-12 months.
The comparison with antidepressants is close to a tie in the short term, with CBT larger at 6-12 months by g=0.34. I treat that as a reason to offer psychotherapy to patients who want durable benefit, while noting the authors’ own caution that few trials support it.
The comparison with other psychotherapies is the result that should change how the field talks about CBT. A g=0.06 difference that vanishes in most sensitivity analyses means the choice between CBT and another psychotherapy is not the decision that determines outcome. Getting a patient into an active, structured psychotherapy is.
Related Studies and Research
Episode 31: Depression Explained, The Biology Behind the Darkness
Episode 32: Depression Recovery Roadmap: A Step-by-Step, Evidence-Based Plan
FAQs
How does CBT compare to antidepressant medications?
CBT did not differ significantly from pharmacotherapies in the short term, and was significantly larger at 6-12 month follow-up (g=0.34, 95% CI: 0.09-0.58). The authors note the number of trials behind that long-term result was small and the difference was not significant in all sensitivity analyses.
Is CBT better than other types of therapy?
CBT was significantly more effective, but the difference was small (g=0.06, 95% CI: 0-0.12) and became non-significant in most sensitivity analyses. The authors conclude that superiority of CBT over other psychotherapies for depression does not emerge clearly from this meta-analysis.
Should I choose CBT alone or combined with medication?
Combined treatment was more effective than pharmacotherapy alone at the short term (g=0.51) and long term (g=0.32), but it was not more effective than CBT alone at either time point. For a patient who prefers to avoid medication, CBT alone is a defensible first step.
How long do CBT effects last?
The benefit of CBT over control conditions was still significant at 6-12 month follow-up. Against pharmacotherapy, CBT was larger at that same 6-12 month window.
Does unguided self-help CBT work?
Yes. CBT delivered as an unguided self-help intervention produced g=0.45 (95% CI: 0.31-0.60). That makes it a usable option when a therapist is not available.
Bottom Line
This meta-analysis of 409 trials with 52,702 patients shows CBT produces a moderate to large benefit against care as usual and waitlist (g=0.79), holding at 6-12 months. It matched antidepressants short term and was larger at 6-12 months (g=0.34), on a small number of trials. Its advantage over other psychotherapies was g=0.06 and did not survive most sensitivity analyses. Combined treatment beat medication alone but not CBT alone. The efficacy of CBT for depression is well documented across formats, ages, target groups and settings. Its superiority over other psychotherapies is not.
